Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm plus ) advanced NSCLC: Updated data from the GioTag real-world study

被引：0
|
作者：
Hochmair, M. J. [1 ,2 ]
Morabito, A. [3 ]
Hao, D. [4 ]
Yang, C-T. [5 ]
Soo, R. [6 ]
Yang, J. C-H. [7 ]
Gucalp, R. [8 ]
Halmos, B. [8 ]
Wang, L. [9 ]
Golembesky, A. [10 ]
Maerten, A. [10 ]
Cufer, T. [11 ]
机构：
[1] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria
[2] Otto Wagner Hosp, Ludwig Boltzmann Inst COPD & Resp Epidemiol, Vienna, Austria
[3] Fdn G Pascale IRCCS, Ist Nazl Tumori, Thorac Med Oncol, Naples, Italy
[4] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[5] Chang Gung Mem Hosp, Dept Thorac Med, Taoyuan, Taiwan
[6] Natl Univ Singapore Hosp, Dept Haematol Oncol, Singapore, Singapore
[7] Natl Taiwan Univ, Canc Ctr, Natl Taiwan Univ Hosp, Taipei, Taiwan
[8] Montefiore Albert Einstein Canc Ctr, Dept Oncol, New York, NY USA
[9] Boehringer Ingelheim Taiwan Ltd, Taipei, Taiwan
[10] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[11] Univ Ljubljana, Univ Clin Golnik, Ljubljana, Slovenia
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1532P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] UpSwinG: real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations.
    Miura, Satoru
    Hsia, Te-Chun
    Hung, Jen-Yu
    Jung, Hyun Ae
    Shih, Jin-Yuan
    Yang, Tsung-Ying
    Park, Cheol-Kyu
    Lee, Seung Hyeun
    Okamoto, Tatsuro
    Ahn, Hee Kyung
    Lee, Yong Chul
    Sato, Yuki
    Lee, Sung Sook
    Mascaux, Celine
    Daoud, Hasan
    Maerten, Angela
    Popat, Sanjay
    CANCER RESEARCH, 2021, 81 (13)
  • [32] Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
    Lu, Shun
    Shih, Jin-Yuan
    Jang, Tae-Won
    Liam, Chong-Kin
    Yu, Yongfeng
    ADVANCES IN THERAPY, 2021, 38 (05) : 2038 - 2053
  • [33] Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naive patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC
    De Marinis, F.
    Laktionov, K. K.
    Poltoratskiy, A.
    Egorova, I.
    Hochmair, M.
    Passaro, A.
    Migliorino, M. R.
    Metro, G.
    Gottfried, M.
    Tsoi, D.
    Ostoros, G.
    Rizzato, S.
    Mukhametshina, G. Z.
    Schumacher, M.
    Novello, S.
    Dziadziuszko, R.
    Tang, W.
    Clementi, L.
    Cseh, A.
    Kowalski, D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [34] Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
    Shun Lu
    Jin-Yuan Shih
    Tae-Won Jang
    Chong-Kin Liam
    Yongfeng Yu
    Advances in Therapy, 2021, 38 : 2038 - 2053
  • [35] Afatinib in Asian and Non-Asian Patients (pts) with EGFR Mutation-Positive (EGFRm plus ) NSCLC Harboring Major Uncommon Mutations
    Yang, J. Chih-Hsin
    Schuler, M.
    Popat, S.
    Miura, S.
    Heeke, S.
    Passaro, A.
    de Marinis, F.
    Park, K.
    Kim, E. S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S31 - S31
  • [36] Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
    Nobuyuki Yamamoto
    Takeshi Mera
    Angela Märten
    Maximilian J. Hochmair
    Advances in Therapy, 2020, 37 : 759 - 769
  • [37] Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
    Yamamoto, Nobuyuki
    Mera, Takeshi
    Maerten, Angela
    Hochmair, Maximilian J.
    ADVANCES IN THERAPY, 2020, 37 (02) : 759 - 769
  • [38] Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG)
    Popat, S.
    Jung, H. A.
    Lee, S. Yup
    Hochmair, M. J.
    Lee, S. H.
    Escriu, C.
    Lee, M. K.
    Migliorino, M. R.
    Lee, Y. C.
    Girard, N.
    Daoud, H.
    Maerten, A.
    Miura, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S971 - S972
  • [39] A combined analysis of two phase IIIb studies of afatinib in EGFR TKI-naive patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC
    de Marinis, F.
    Tu, H.
    Laktionov, K. K.
    Feng, J.
    Poltoratskiy, A.
    Zhao, J.
    Egorova, I.
    Tan, E-H.
    Gottfried, M.
    Lee, V.
    Kowalski, D. M.
    Yang, C-T.
    Srinivasa, B. J.
    Passaro, A.
    Clementi, L.
    Tang, W.
    Huang, D. C-L.
    Cseh, A.
    Zhou, C.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2019, 30 : 600 - 600
  • [40] Real-world EGFR testing in patients with advanced EGFRm NSCLC in Belgium (REVEAL)
    Cuppens, K.
    Lodewyckx, L.
    Demedts, I.
    Decoster, L.
    Colinet, B.
    Deschepper, K.
    Janssens, A.
    Pauwels, P.
    Galdermans, D.
    Pieters, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S1117 - S1117
12345